262 related articles for article (PubMed ID: 7637143)
1. Long-term survival among men with conservatively treated localized prostate cancer.
Albertsen PC; Fryback DG; Storer BE; Kolon TF; Fine J
JAMA; 1995 Aug 23-30; 274(8):626-31. PubMed ID: 7637143
[TBL] [Abstract][Full Text] [Related]
2. 20-year outcomes following conservative management of clinically localized prostate cancer.
Albertsen PC; Hanley JA; Fine J
JAMA; 2005 May; 293(17):2095-101. PubMed ID: 15870412
[TBL] [Abstract][Full Text] [Related]
3. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer.
Albertsen PC; Hanley JA; Gleason DF; Barry MJ
JAMA; 1998 Sep; 280(11):975-80. PubMed ID: 9749479
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer and the Will Rogers phenomenon.
Albertsen PC; Hanley JA; Barrows GH; Penson DF; Kowalczyk PD; Sanders MM; Fine J
J Natl Cancer Inst; 2005 Sep; 97(17):1248-53. PubMed ID: 16145045
[TBL] [Abstract][Full Text] [Related]
5. Results of conservative management of clinically localized prostate cancer.
Chodak GW; Thisted RA; Gerber GS; Johansson JE; Adolfsson J; Jones GW; Chisholm GD; Moskovitz B; Livne PM; Warner J
N Engl J Med; 1994 Jan; 330(4):242-8. PubMed ID: 8272085
[TBL] [Abstract][Full Text] [Related]
6. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.
Albertsen PC; Hanley JA; Penson DF; Barrows G; Fine J
J Urol; 2007 Mar; 177(3):932-6. PubMed ID: 17296379
[TBL] [Abstract][Full Text] [Related]
7. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
[TBL] [Abstract][Full Text] [Related]
8. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
9. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
10. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5.
Patel AA; Chen MH; Renshaw AA; D'Amico AV
JAMA; 2007 Oct; 298(13):1533-8. PubMed ID: 17911498
[TBL] [Abstract][Full Text] [Related]
11. External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.
Daskivich TJ; Thomas IC; Luu M; Shelton JB; Makarov DV; Skolarus TA; Leppert JT
J Urol; 2019 Sep; 202(3):518-524. PubMed ID: 31009286
[TBL] [Abstract][Full Text] [Related]
12. The impact of co-morbidity on life expectancy among men with localized prostate cancer.
Albertsen PC; Fryback DG; Storer BE; Kolon TF; Fine J
J Urol; 1996 Jul; 156(1):127-32. PubMed ID: 8648773
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.
Potosky AL; Haque R; Cassidy-Bushrow AE; Ulcickas Yood M; Jiang M; Tsai HT; Luta G; Keating NL; Smith MR; Van Den Eeden SK
J Clin Oncol; 2014 May; 32(13):1324-30. PubMed ID: 24638009
[TBL] [Abstract][Full Text] [Related]
14. [Competitive morbidity ant its impact on life expectancy: evaluation and inclusion in the therapeutic decision regarding localized prostatic cancer].
Soulié M; Villers A; Richaud P; Prapotnich D; Ruffion A; Grosclaude P
Prog Urol; 2001 Dec; 11(6):1195-204. PubMed ID: 11859652
[TBL] [Abstract][Full Text] [Related]
15. Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.
Sammon JD; Abdollah F; Reznor G; Pucheril D; Choueiri TK; Hu JC; Kim SP; Schmid M; Sood A; Sun M; Kibel AS; Nguyen PL; Menon M; Trinh QD
Eur Urol; 2015 Jul; 68(1):32-9. PubMed ID: 25457017
[TBL] [Abstract][Full Text] [Related]
16. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy).
Tewari A; Raman JD; Chang P; Rao S; Divine G; Menon M
Urology; 2006 Dec; 68(6):1268-74. PubMed ID: 17169648
[TBL] [Abstract][Full Text] [Related]
18. Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection.
Egevad L; Granfors T; Karlberg L; Bergh A; Stattin P
J Urol; 2002 Aug; 168(2):509-13. PubMed ID: 12131299
[TBL] [Abstract][Full Text] [Related]
19. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
[TBL] [Abstract][Full Text] [Related]
20. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
Carter CA; Donahue T; Sun L; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Jackmaan S; Moul JW
J Clin Oncol; 2003 Nov; 21(21):4001-8. PubMed ID: 14581423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
